Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
Quartino AL, Li H, Jin JY, Wada DR, Benyunes MC, McNally V, Viganò L, Nijem I, Lum BL, Garg A. Quartino AL, et al. Among authors: lum bl. Cancer Chemother Pharmacol. 2017 Feb;79(2):353-361. doi: 10.1007/s00280-016-3218-0. Epub 2017 Jan 10. Cancer Chemother Pharmacol. 2017. PMID: 28074265 Free PMC article.
Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
Quartino AL, Hillenbach C, Li J, Li H, Wada RD, Visich J, Li C, Heinzmann D, Jin JY, Lum BL. Quartino AL, et al. Among authors: lum bl. Cancer Chemother Pharmacol. 2016 Jan;77(1):77-88. doi: 10.1007/s00280-015-2922-5. Epub 2015 Dec 8. Cancer Chemother Pharmacol. 2016. PMID: 26645407 Free PMC article. Clinical Trial.
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
Cortés J, Swain SM, Kudaba I, Hauschild M, Patel T, Grincuka E, Masuda N, McNally V, Ross G, Brewster M, Marier JF, Trinh MM, Garg A, Nijem I, Visich J, Lum BL, Baselga J. Cortés J, et al. Among authors: lum bl. Anticancer Drugs. 2013 Nov;24(10):1084-92. doi: 10.1097/CAD.0000000000000016. Anticancer Drugs. 2013. PMID: 23969513 Clinical Trial.
Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.
Xu N, Redfern CH, Gordon M, Eppler S, Lum BL, Trudeau C. Xu N, et al. Among authors: lum bl. Cancer Chemother Pharmacol. 2014 Dec;74(6):1251-60. doi: 10.1007/s00280-014-2603-9. Epub 2014 Oct 26. Cancer Chemother Pharmacol. 2014. PMID: 25344761 Free PMC article. Clinical Trial.
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.
Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, Rudin CM, Reddy JC, Low JA, Lorusso PM. Graham RA, et al. Among authors: lum bl. Clin Cancer Res. 2011 Apr 15;17(8):2512-20. doi: 10.1158/1078-0432.CCR-10-2736. Epub 2011 Feb 7. Clin Cancer Res. 2011. PMID: 21300760 Free PMC article. Clinical Trial.
114 results